Metabolic & weight
Mazdutide
Also called IBI362, LY3305677
Mazdutide is a weekly shot that acts on both the GLP-1 and glucagon receptors. It was approved in China in June 2025 for weight management, the first drug of its type approved anywhere. It is not approved in the United States.
Overview
Mazdutide is a weekly shot that acts on both the GLP-1 and glucagon receptors. It was approved in China in June 2025 for weight management, the first drug of its type approved anywhere. It is not approved in the United States.
How it works
Established in trials as a dual GLP-1 and glucagon receptor agonist. GLP-1 action reduces appetite and improves blood sugar; glucagon action is proposed to increase energy use and reduce liver fat. In GLORY-1 people with high liver fat saw large liver-fat reductions.
What research shows
- GLORY-1 phase 3 RCT in Chinese adults with overweight or obesity (n=610, 48 weeks, NEJM 2025): weight change −11.0% (4 mg) and −14.0% (6 mg) vs +0.3% placebo.
- In GLORY-1, 49.5% on 6 mg lost at least 15% of body weight vs 2.0% on placebo.
- Participants with high baseline liver fat had liver-fat reductions of about 66–80% vs 5% on placebo (company report).
Doses studied in people
| Study or label | Dose used | Source |
|---|---|---|
| GLORY-1 phase 3 RCT, Chinese adults with obesity/overweight (n=610) | 4 mg or 6 mg once weekly, subcutaneous, 48 weeks | 1 |
Doses are from the GLORY-1 phase 3 trial; the approved Chinese label dosing was not verified from a primary source.
Read this first: these are the amounts given to participants in published studies or written on official prescribing labels, reported for reference. They are not recommendations. Trial doses were chosen for specific patients under medical supervision, and a dose that is safe in one person can be harmful in another.
Weekly protocol
How the schedule looks week by week. Each chart says where it comes from: a prescribing label, a clinical trial, or a protocol commonly reported online.
Phase 2 trial in Chinese adults (6 mg arm)
Clinical trialOne week
Once weekly · Subcutaneous injection
Syringe units (U-100)
Dose by week
Supplies for one course (estimate)
Counts only. This site does not sell or link to supplies.
Reference only, not a recommendation. Label and trial schedules were set for specific patients under medical supervision. Use the calculator only to understand the arithmetic.
Vial math
Many research vials hold 5 or 10 mg of powder. This table shows how much ends up in each mark on a U-100 insulin syringe for common amounts of added liquid. It is arithmetic only, not a dose.
| Vial | Liquid added | Concentration | Per unit (0.01 mL) | |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 50 mcg | Open in calculator |
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg | Open in calculator |
| 5 mg | 3 mL | 1.67 mg/mL | 16.7 mcg | Open in calculator |
| 10 mg | 1 mL | 10 mg/mL | 100 mcg | Open in calculator |
| 10 mg | 2 mL | 5 mg/mL | 50 mcg | Open in calculator |
| 10 mg | 3 mL | 3.33 mg/mL | 33.3 mcg | Open in calculator |
More sizes: all vial sizes · How this works: Syringes and units · Reconstitution guide.
Safety
- Most common side effects were gastrointestinal, mostly mild to moderate (GLORY-1).
- Discontinuation due to side effects was low in GLORY-1: 1.5% (4 mg), 0.5% (6 mg), 1.0% (placebo).
- Trial data so far are mainly in Chinese adults; long-term and cardiovascular safety are not established.
Report side effects of any drug or product to the FDA through MedWatch. For a possible poisoning in the US, call Poison Control at 1-800-222-1222.
Legal status
- FDA
- Not FDA-approved; investigational in the US.
- Compounding
- Not eligible for lawful US compounding (not an approved drug or listed bulk substance).
- Sports (WADA)
- Not named on the WADA list; would likely fall under S0 (non-approved substances) outside approved markets — confirm with your anti-doping body.
- Other
- Approved by China's NMPA (June 2025) for chronic weight management in adults with BMI ≥28, or ≥24 with a weight-related condition.
Rules change often. See Legal status of peptides for how these categories work.
History
Licensed by Innovent Biologics from Eli Lilly for development in China. The phase 3 GLORY-1 trial was published in NEJM in June 2025. China's NMPA approved mazdutide for chronic weight management in June 2025 (announced June 27, 2025), making it the first approved dual GCG/GLP-1 agonist.
Common questions
Is mazdutide approved anywhere?
What does the research show?
Does mazdutide affect liver fat?
The company reported that GLORY-1 participants with high liver fat saw reductions of about 66% to 80% vs 5% on placebo 2.
What doses were studied?
GLORY-1 tested 4 mg or 6 mg once weekly by injection for 48 weeks 1. The approved Chinese label dosing was not verified from a primary source.
Related compounds
Survodutide
BI 456906
Survodutide is an experimental weekly shot that acts on both the glucagon and GLP-1 receptors.
Retatrutide
LY3437943 · triple agonist
Retatrutide is an experimental weekly shot from Eli Lilly that acts on three hormone receptors: GIP, GLP-1, and glucagon.
Semaglutide
Wegovy · Ozempic
Semaglutide is a long-acting copy of the gut hormone GLP-1.
Sources
Last reviewed 2026-10-25 · How we research · Found an error? See our corrections policy.